Core decompression (CD) is an important method for the treatment of osteonecrosis of the femoral head (ONFH). Few articles investigate the influence of core decompression on outcomes of ONFH. This study was carried out to observe the safety and effectiveness of core decompression in the treatment of ONFH.
Methods
A comprehensive literature search of databases including PubMed, Embase, and Cochrane Library was performed to collect the related studies. The medical subject headings used were “femur head necrosis” and “Core decompression.” The relevant words in title or abstract included but not limited to “Osteonecrosis of the Femoral Head,” “femoral head necrosis,” “avascular necrosis of femoral head,” and “ischemic necrosis of femoral head.” The methodological index for nonrandomized studies was adopted for assessing the studies included in this review.
Results
Thirty-two studies included 1865 patients (2441 hips). Twenty-one studies (1301 hips) using Ficat staging standard, 7 studies (338hips) using Association Research Circulation Osseous (ARCO) staging standard, and University of Pennsylvania system for staging avascular necrosis (UPSS) staging criteria for 4 studies (802 hips). All the studies recorded the treatment, 22 studies (1379 hips) were treated with core decompression (CD) alone, and 7 studies (565 hips) were treated with core decompression combined with autologous bone (CD Autologous bone). Nine subjects (497 hips) were treated with core decompression combined with autologous bone marrow (CD Marrow). Twenty-seven studies (2120 hips) documented the number of conversion to total hip replacement (THA), and 26 studies (1752hips) documented the number of radiographic progression (RP). Twenty-one studies recorded the types of complications and the number of cases, a total of 69 cases. The random-effect model was used for meta-analysis, and the results showed that the overall success rate was 65%. The rate of success showed significant difference on the outcomes of different stages. The rate of success, conversion to THA, and radiographic progression showed significant difference on the outcomes of ONFH using different treatments.
Conclusions
Core decompression is an effective and safe method of treating ONFH. The combined use of autologous bone or bone marrow can increase the success rate. For advanced femoral head necrosis, the use of CD should be cautious. High-quality randomized controlled trials and prospective studies will be necessary to clarify the effects of different etiology factors, treatments, and postoperative rehabilitation. Until then, the surgeon can choose core decompression to treat ONFH depending on the patient’s condition.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ARCO
Association Research Circulation Osseous
BMP
Bone morphogenetic proteins
CD Autologous bone
Core decompression combined with autologous bone
CD Marrow
Core decompression combined with autologous bone marrow
CD
Core decompression
ES
Effect size
HHS
Harris hip score
NICE
National Institute for Clinical Excellence
NOS
Newcastle-Ottawa Scale
ONFH
Osteonecrosis of the femoral head
RP
Radiographic progression
THA
Total hip replacement
UPSS
University of Pennsylvania system for staging avascular necrosis
Introduction
Osteonecrosis of the femoral head (ONFH) is interrupted or damaged by the blood supply to the femoral head, causing death and subsequent repair of bone cells and bone marrow components, which in turn leads to structural changes in the femoral head and collapse of the femoral head, causing joint pain and dysfunction in patients, and the disease is difficult to heal [1‐3]. High disability rate is a common refractory disease in the field of orthopedics. There is a lack of effective treatment in clinical practice [4]. Most patients have to undergo total hip arthroplasty. The search for minimally invasive, safe, and effective treatment of femoral head necrosis has been a hot topic in orthopedic research [5]. Core decompression (CD) reduces the pressure in the bone, opens up the hardening zone that hinders the repair of osteonecrosis, stimulates the formation of blood vessels around the decompression tunnel, enhances the replacement of the new bone, and delays the progression of osteonecrosis [2‐5]. A study confirms that CD combined with cytotherapy is a relatively good treatment for reducing the failure rate of early and mid-term ONFH patients [6]. Another study confirmed that CD combined with autologous bone marrow stem cells has achieved good results in early ONFH patients [7]. The purpose of this study was to summarize the efficacy of core decompression in the treatment of ONFH, to analyze the factors affecting the core decompression treatment of ONFH, and to evaluate the difference between the current core decompression and combined autologous bone or bone marrow therapy. Provide some useful advice for surgeons using core decompression therapy for ONFH.
Materials and methods
Literature search
PubMed-MEDLINE and Ovid-Embase were adopted for the comprehensive literature searches using a combination of the medical subject headings and relevant words in the title or abstract. The medical subject headings used were “core decompression” and “femur head necrosis.” The relevant words in the title or abstract included “femoral head necrosis,” “avascular necrosis of femoral head,” “ischemic necrosis of femoral head,” and “Osteonecrosis of the femoral head.” A cross-reference search was performed to identify additional studies. The search time is from January 1, 1980, to March 31, 2019, and the language is limited to Chinese and English. All retrieved records were added to an EndNote (Version X7; Thomson Reuters, New York, NY) library.
Anzeige
Inclusion criteria
The inclusion criteria are as follows:
1.
The published core decompression treatment of femoral head necrosis; the average follow-up time ≥ 1 year; the patient’s basic information (age at the time of treatment, gender, history of previous hip disease, etc.) record is complete; and if there is a control group, the two groups of patients are required to have no significant differences in basic information (age at the time of treatment, gender, history of previous hip disease, etc.).
2.
Patients with femoral head necrosis were diagnosed by clinical physical examination and imaging and required to be treated with core decompression.
3.
All of the studies are core decompression treatment of femoral head necrosis, and patients undergo treatment to promote healing of the surgical site.
4.
The main indicators of each study were number of successful operations, radiographic progression, complications, and secondary operations.
Exclusion criteria
The exclusion criteria are as follows:
1.
The studies that were not associated with core decompression for femoral head necrosis
2.
The number of successful hips after core decompression therapy was not clearly recorded, or a clear definition of surgical success was not given.
3.
No analysis of prognostic factors
4.
Review, case report, meetings abstracts, animal studies, editorial letters, guidance or comments, etc.
5.
Repeated studies
6.
Lower literature quality scores
Quality assessment
The case series study used the National Institute for Clinical Excellence (NICE) case series scoring standard for quality evaluation. The case-control study used the Newcastle-Ottawa Scale (NOS) for quality evaluation. The scale was divided into three parts: “selection,” “comparability,” and “exposure.” The random control trial (RCT) used a modified Jadad scale for quality assessment, including randomized mass, grouped concealment, double-blind, and sample outcomes. Two researchers independently conducted a rigorous quality evaluation of the retrieved literature in accordance with the above inclusion and exclusion criteria. When there were different opinions, the discussion was conducted and a third researcher was invited to participate in the review.
Data extraction
Relevant information, including first author, year of publication, study design, country of study, total number and age of ONFH patients, use of autologous bone or bone marrow during surgery, and preoperative and postoperative hip staging and criteria, was extracted. The clinical outcomes of our study included overall surgical success rate (definition of successful surgery: during follow-up, Harris hip score (HHS) ≥ 70, no further THA surgery required, no radiographic progression), rate of conversion to THA, rate of radiographic progression, rate of success in different stages, and complications such as fracture, surgical site pain, hematoma, deep vein thrombosis, and infection.
Anzeige
Statistical analysis
Descriptive analysis of indicators that cannot be combined or that are not suitable for consolidation. In our study, we used the extracted raw data to calculate the rate of conversion to THA, the rate of radiological progression, the success rate of different treatment methods, and the success rate of different stages in each study. According to the sample size corresponding to each group rate, the corresponding standard deviation is calculated, and the standard deviation of the rate and rate is used as the effect amount for meta-analysis. X2 test was used for quantification of statistical inconsistency between studies, and I2 values showed the degree of heterogeneity. When significant heterogeneity (P ≤ 0.1 and I2 ≥ 50%) was detected, studies were combined using a random-effects model. When no significant heterogeneity (P > 0.1 and I2 < 50%) was detected, studies were combined using a fixed-effects model. The differences between subgroups were further tested, and a value of P less than 0.05 was considered statistically significant.
The X2 test was used to compare the success rate of Ficat I, II, and III stage, the success rate of different treatment methods, the rate of conversion to THA of different treatment methods, and the radiographic progression rate of different treatment methods. The test level α value was 0.05. The process was statistically analyzed using the SPSS 20.0 statistical software package.
Results
Literature search
A flow diagram explaining the literature search strategy and study selection is shown in Fig. 1. A total of 917 articles were found by computer search, of which 384 were PubMed and 533 were retrieved from Embase (Additional file 1). Through the check processing of EndNote software, it was found that 509 articles were duplicated, and the remaining 408 articles of the title and abstract deletion of the literature were not in conformity with the remaining 63 articles after inclusion of the exclusion criteria. In order to further screen the full text of the reading, the remaining 32 studies were reproduced and the quality was completed. The evaluation included 3 RCTs [8‐10], 26 case series studies [5, 11‐35], and 3 case-control studies [36‐38].
Fig. 1
Flowchart of studies identification and selection
×
Study characteristics
The basic characteristics of those studies are shown in Table 1. The study included 1865 patients (2441 hips) with an average age of approximately 37.72 (12–85) years, a female ratio of approximately 35.57%, and an average follow-up of 54.3 (2–228) months. The 32 studies included 3 RCTs, 26 case series studies, and 3 case-control studies. The RCT study used a modified version of the Jadad scale for quality evaluation, the average score of the three RCT studies was 5.67. The 26 case series used the NICE case series scoring criteria for quality evaluation, the average score of the study was 5.88. Three case-control studies used NOS scales for quality assessment with an average score of 8.67.
Table 1
Basic characteristics of included studies
Author
Year
Study type
Nation
Male/female
Age
Hips
Therapies
Evaluation standard
Study quality
Gangji
2011
RCT
Belgium
9/10
43.86
24
Control: CD
Trial: CD+Marrow
Jadad
6
Zhao
2012
RCT
China
53/47
33.25
97
Control: CD
Trial: CD+Marrow
Jadad
6
Pepke
2016
RCT
German
21/3
44.4
25
Control: CD
Trial: CD+Marrow
Jadad
5
Zhang HJ
2010
Case-control
China
20/12
36.3
39
Control: CD
Trial: CD+Marrow
NOS
8
Zhuo NQ
2012
Case-control
China
16/12
31.9
33
Control: CD
Trial: CD+A.B
NOS
9
Guo HS
2018
Case-control
China
56/20
44.32
76
Control: CD
Trial: CD+A.B
NOS
9
Warner
1987
Case series
USA
13/12
38
39
CD
NICE
6
Tooke
1988
Case series
USA
14/19
40
45
CD
NICE
6
Lausten
1990
Case series
Denmark
24/3
40
29
CD
NICE
7
Learmonth
1990
Case series
South Africa
21/11
37
41
CD
NICE
5
Fairbank
1994
Case series
USA
45/45
40
128
CD
NICE
6
Smith
1995
Case series
USA
59/33
41
114
CD
NICE
6
Markel
1996
Case series
USA
12/33
38.6
54
CD
NICE
6
Mont
1997
Case series
USA
22/28
34
79
CD
NICE
5
Powell
1997
Case series
USA
10/12
35
34
CD
NICE
6
Iorio
1998
Case series
USA
NA
40.8
33
CD
NICE
5
Bozic
1999
Case series
USA
21/13
38
54
CD
NICE
6
Steinberg
2001
Case series
USA
123/85
37
312
CD+A.B
NICE
5
Hernigou
2002
Case series
USA
75/41
31
189
CD+Marrow
NICE
6
Lieberman
2004
Case series
USA
6/9
47
17
CD
NICE
5
Belmar
2004
Case series
USA
NA
NA
302
CD
NICE
5
Song
2007
Case series
South Korea
120/16
36.1
163
CD
NICE
6
Li YP
2007
Case series
China
19/6
37.2
36
CD+A.B
NICE
5
Ji WF
2008
Case series
China
71/16
47
103
CD+Marrow
NICE
5
Xu WH
2009
Case series
China
26/14
35.6
42
CD+A.B
NICE
5
Wang
2010
Case series
China
36/9
37.5
59
CD+Marrow
NICE
5
Cao B
2010
Case series
China
37/18
39.8
61
CD+A.B
NICE
5
Yang J
2010
Case series
China
50/5
35
85
CD
NICE
5
Zhao Y
2011
Case series
China
16/6
Range (16–51)
25
CD
NICE
6
Chotivichit
2012
Case series
Thailand
3/7
36.18
11
CD+Marrow
NICE
6
Chotivichit
2014
Case series
Thailand
18/14
31.9
34
CD+Marrow
NICE
6
Chen XT
2015
Case series
China
31/19
36.2
58
CD+A.B
NICE
6
Note: NA not available, CD core decompression, CD+Marrow core decompression combined with autologous bone marrow, CD+A.B core decompression combined with autologous bone, NICE National Institute for Clinical Excellence, NOS Newcastle-Ottawa Scale
Clinical outcomes
Clinical outcomes of included studies are shown in Table 2. Meta-analysis using a random-effects model due to heterogeneity showed an overall effect size (ES) of 0.65 (95% CI (0.60, 0.70)) (Fig. 2), as shown in the published core decompression treatment of the femoral head necrosis. In the literature, the overall success rate after surgery was 65%.
Table 2
Clinical outcomes of included studies
Author
Year
Therapies
Hips
Hips to THA
Hips with RP
Staging methods
Complications
Follow-up (month)
Gangji
2011
Control: CD
Trial: CD+Marrow
Control: 11
Trial: 13
Control: 3
Trial: 2
Control: 8
Trial: 3
ARCO
Pain: 4
Infection: 1
60
Zhao
2012
Control: CD
Trial: CD+Marrow
Control: 44
Trial: 53
Control: 5
Trial: 2
Control: 10
Trial: 2
ARCO
None
60
Pepke
2016
Control: CD
Trial: CD+Marrow
Control: 14
Trial: 11
Control: 6
Trial: 4
Control: 6
Trial: 4
ARCO
NA
24
Zhang HJ
2010
Control: CD
Trial: CD+Marrow
Control: 15
Trial: 24
NA
Control: 2
Trial: 1
ARCO
None
18
Zhuo NQ
2012
Control: CD
Trial: CD+A.B
Control: 12
Trial: 21
Control: 4
Trial: 1
Control: 4
Trial: 1
Ficat
None
30
Guo HS
2018
Control: CD
Trial: CD+A.B
Control: 41
Trial: 35
NA
Control: 6
Trial: 1
Ficat
Pain: 1
30
Warner
1987
CD
39
19
23
Ficat
Fracture: 1
Hematoma: 1
16
Tooke
1988
CD
45
16
16
Ficat
Fracture: 1
36
Lausten
1990
CD
29
15
11
Ficat
Pain: 1
17.2
Learmonth
1990
CD
41
18
34
Ficat
Fracture: 1
32
Fairbank
1994
CD
128
55
81
Ficat
Fracture: 4
Perforation of femoral head: 1
Deep venous thrombosis: 2
Retained drain: 1
132
Smith
1995
CD
114
64
81
Ficat
Infection: 3
Fracture: 2
Hematoma: 2
Non-fatal pulmonary embolism: 1
Deep venous thrombosis: 1
Reflex sympathetic dystrophy: 1
40
Markel
1996
CD
54
26
NA
Ficat
Fracture: 2
Infection: 1
27.1
Mont
1997
CD
79
37
37
Ficat
NA
144
Powell
1997
CD
34
6
9
Ficat
None
48
Iorio
1998
CD
33
11
17
Ficat
NA
60
Bozic
1999
CD
54
28
34
Ficat
Fracture: 1
Hematoma: 1
97
Steinberg
2001
CD+A.B
312
113
113
UPSS
NA
48
Hernigou
2002
CD+Marrow
189
34
52
Ficat
Pain: 1
Pneumonia: 1
Alloimmunization: 1
84
Lieberman
2004
CD
17
3
3
Ficat
Pain: 4
53
Belmar
2004
CD
302
113
NA
UPSS
NA
46
Song
2007
CD
163
50
NA
Ficat
Heterotopic ossifications: 23
Fracture: 1
87
Li YP
2007
CD+A.B
36
4
4
ARCO
NA
23.4
Ji WF
2008
CD+Marrow
103
NA
NA
UPSS
None
26
Xu WH
2009
CD+A.B
42
NA
NA
Ficat
None
38
Wang
2010
CD+Marrow
59
7
14
ARCO
NA
27.6
Cao B
2010
CD+A.B
61
NA
22
Ficat
NA
26.4
Yang J
2010
CD
85
6
19
UPSS
None
57.6
Zhao Y
2011
CD
25
2
NA
Ficat
NA
73
Chotivichit
2012
CD+Marrow
11
2
8
Ficat
NA
42.6
Chotivichit
2014
CD+Marrow
34
10
9
Ficat
Pain: 4
25.8
Chen XT
2015
CD+A.B
58
11
11
ARCO
NA
34.05
Note: NA not available, CD core decompression, CD+Marrow core decompression combined with autologous bone marrow, CD+A.B core decompression combined with autologous bone, THA total hip replacement, RP radiographic progression
Fig. 2
Overall success rate meta-analysis
×
A total of 29 studies [5, 8, 10, 12‐26, 28‐38] (2095 hips) recorded the etiologic factors and the number of hips. The most common etiologic factor was steroids (894 hips, 42.7%), followed by alcohol (584 hips, 27.9%) and idiopathic (299 hips, 14.3%). The specific etiologic factors and number of hips are shown in Fig. 3.
Fig. 3
Etiologic factors
×
A total of 21 studies [8, 10, 12, 14‐16, 18‐20, 22‐26, 29, 30, 33, 34, 36‐38] (1440 hips) recorded the type of complications and the number of cases, a total of 69 hips (4.79% 69/1440). Common complications are heterotopic ossifications (23 hips, 33.3%), pain (15 hips, 21.7%), and fracture (13 hips, 18.8%), and the specific complications and the number of hips are shown in Table 2.
We pooled analyses on the overall success rate; success rate of Ficat I, II, and III stage; the success rate of different treatment methods; the rate of conversion to THA of different treatment methods; and the radiographic progression rate of different treatment methods were conducted based on the data from the 32 studies.
Anzeige
Success rate of different stages
All studies recorded the staging of preoperative femoral head necrosis. Of these, 21 studies [12‐25, 27, 30, 31, 33, 34, 36, 38] (1301 hips) used Ficat staging criteria, 17 studies [12, 13, 15‐25, 30, 31, 34, 36] included stage I cases, 21 studies [12‐25, 27, 30, 31, 33, 34, 36, 38] included stage II cases, 16 studies [12‐16, 18, 20, 21, 23‐25, 27, 30, 31, 33, 34] included stage III cases, and only one study included stage IV cases; 7 studies [8‐10, 28, 32, 35, 37] (338 hips) used the Association Research Circulation Osseous (ARCO) staging criteria, 6 studies [8, 10, 28, 32, 35, 37] included stage I cases, and 7 [8‐10, 28, 32, 35, 37] studies included stage II cases, and 2 studies [28, 35] included stage III cases; 4 studies [5, 11, 26, 29] (802 hips) used the University of Pennsylvania system for staging avascular necrosis (UPSS) staging criteria, 4 studies [5, 11, 26, 29] included stage I cases, 4 studies [5, 11, 26, 29] included stage II cases, 3 studies [5, 11, 26] included stage III cases, and 2 studies [5, 11] included stage IV cases (Fig. 4).
Fig. 4
Stage and success rate
×
Considering the impact of the study and the number of cases on the outcome, this article only compares the success rates of Ficat I (220/280 78.29%), II (383/645 59.38%), and III (59/215 27.44%). Statistical analysis showed that the success rate of Ficat I (220/280 78.29%) > II (383/645 59.38%) > III (59/215 27.44%), the difference is statistically significant (X2 = 130.435, P < 0.05). Ficat I success rate and Ficat II success rate, the difference is statistically significant (X2 = 30.820, P < 0.05), Ficat II success rate and Ficat III success rate, the difference was statistically significant (X2 = 65.844, P < 0.05), Ficat I success rate and Fica III success rate, the difference is statistically significant (X2 = 127.980, P < 0.05).
Success rate of different treatments
Treatment was documented in all studies, 22 studies [8‐12, 15, 17‐25, 29, 31, 33, 34, 36‐38] (1379 hips) with core decompression (CD), and 5 studies [5, 27, 28, 36, 38] (565 hips) with core decompression and autologous bone (CD+A.B); 9 studies [8‐10, 13, 14, 16, 26, 35, 37] (497 hips) used core decompression in combination with autologous bone marrow (CD+Marrow).
Among the 32 studies using CD, CD+Marrow, and CD+A.B to treat ONFH, a total of 2441 hips were pooled into the meta-analysis on the success rate of different treatment methods, the control group and the experimental group of the case-control study and the RCT study were respectively considered as two groups of studies. The overall ES was 0.65 (95% CI, 0.60–0.71). In subgroup analysis, the ES and 95% CI were calculated as 0.57 (95% CI, 0.50–0.61), 0.74 (95% CI, 0.66–0.83), and 0.81 (95% CI, 0.69–0.92) in CD, CD+Marrow, and CD+A.B subgroup, respectively, as shown in Fig. 5. Moreover, the differences between the 3 subgroups were statistically significant (P < 0.05).
Fig. 5
Meta-analysis of success rates for different treatments (C, control group; T, trial group)
×
Anzeige
In order to clarify the differences between the three treatment methods, we performed an X2 test on the success rate. Statistical results display: success rate of CD and success rate of CD+Marrow, the difference is statistically significant (X2 = 53.236, P < 0.05); success rate of CD and success rate of CD+A.B, the difference was statistically significant (X2 = 36.245, P < 0.05); and success rate of CD+Marrow and success rate of CD+A.B, the difference is statistically significant (X2 = 2.067, P = 0.151).
Rate of conversion to THA
Conversion to THA was recorded in 27 studies [5, 8‐25, 28, 29, 31‐36] using CD, CD+Marrow and CD+A.B for treatment of ONFH, a total of 2120 hips were pooled into the meta-analysis on rate of conversion to THA, the control group and the experimental group of the case-control study and the RCT study were respectively considered as two groups of studies. A conversion to THA was seen in 677 hips, which presented an overall ES of 0.28 (95% CI, 0.22–0.34). In subgroup analysis, the ES and 95% CI were calculated as 0.34 (95% CI, 0.26–0.42), 0.16 (95% CI, 0.08–0.24), and 0.18 (95% CI, 0.02–0.34) in CD, CD+Marrow, and CD+A.B subgroup, respectively, as shown in Fig. 6. Furthermore, the differences between the 3 subgroups were statistically significant (P < 0.05).
Fig. 6
Conversion THA rate meta-analysis (C, control group; T, trial group)
×
In order to clarify the differences between the three treatment methods, we performed an X2 test on the rate of conversion to THA. Statistical results display: CD and CD+Marrow rate of conversion to THA, the difference is statistically significant (X2 = 54.556, P < 0.05), CD and CD+A.B rate of conversion to THA, the difference is statistically significant (X2 = 6.614, P < 0.05), CD+Marrow and CD+A.B rate of conversion to THA, the difference is statistically significant (X2 = 20.565, P < 0.05).
Rate of radiographic progression
Radiographic progression was recorded in 26 studies [5, 8‐10, 12‐19, 21‐25, 27‐29, 32, 33, 35‐38] using CD, CD+Marrow and CD+A.B for treatment of ONFH, a total of 1752 hips were pooled into the meta-analysis on rate of radiographic progression, the control group and the experimental group of the case-control study and the RCT study were respectively considered as two groups of studies. A radiographic progression was seen in 646 hips, which presented an overall ES of 0.35 (95% CI, 0.27–0.42). In subgroup analysis, the ES and 95% CI were calculated as 0.43 (95% CI, 0.32–0.54), 0.27 (95% CI, 0.17–0.32), and 0.18 (95% CI, 0.02–0.35) in CD, CD+Marrow, and CD+A.B subgroup, respectively, as shown in Fig. 7. Furthermore, the differences between the 3 subgroups were statistically significant (P < 0.05).
Fig. 7
Rate of radiographic progression meta-analysis (C, control group; T, trial group)
×
Anzeige
In order to clarify the differences between the three treatment methods, we performed an X2 test on the rate of radiographic progression. Statistical results display CD and CD+Marrow rate of radiographic progression, the difference is statistically significant (X2 = 66.406, P < 0.05); CD and CD+A.B rate of radiographic progression, the difference was statistically significant (X2 = 47.894, P < 0.05); CD+Marrow and CD+A.B rate of radiographic progression, the difference is statistically significant (X2 = 3.420, P = 0.064).
Discussion
The core decompression can be targeted to scrape the lesion to the peripheral wall of the bone, which is obviously oozing, that is, close to the normal bone tissue, effectively improving the blood circulation of the bone bed, facilitating the growth of the blood vessel along the tunnel into the femoral head and promoting the repair of the femoral head [39, 40]. Common surgical procedures include core decompression, core decompression plus autologous bone marrow and core decompression plus autologous bone grafting. This study has systematically reviewed the efficacy of core decompression therapy for ONFH. We analyzed the etiology factors, the type of complications and the number of hips, the influence of different preoperative staging on the prognosis, the success rate of different treatment methods, the rate of conversion to THA, and the rate of radiographic progression.
Twenty-nine studies (2095 hips) clearly documented the etiologic factors, mainly steroid and alcohol. However, each study was unable to provide the final treatment outcome for each of the etiologic factors, and we were unable to analyze the impact of the etiologic factors on the prognosis. Review literature found that alcohol and steroid are common causes of ONFH [41, 42], drinking alcohol and applying corticosteroids can cause lipid metabolism disorder [43, 44]. It leads to an increase in the volume of fat cells, fat embolism, etc. which plays an important role in the whole process of femoral head necrosis [45]. From an etiological perspective, it is an important measure to stay away from these risk factors while treating.
Complications were described in 21 studies (1440 hips). Due to the lack of information, there was no detailed statistical analysis of complications, only a rough calculation of the overall complication rate (4.79% 69/1440). Complications were described in 21 studies.
Of the 32 studies included, a total of three staging criteria were used, Ficat, ARCO, and UPSS, respectively. Considering the effect of the number of studies and the sample size on the results, only compare the success rates of the included Ficat I, II, and III cases. The success rate was I > II > III, and the difference was statistically significant. It is proved that preoperative staging is an important factor affecting postoperative, and the success rate of stage III is only 27.44%. The authors believe that CD should be considered carefully for cases of stage III. This procedure is especially suitable for young patients with early femoral head necrosis, for delaying or avoiding total hip replacement is of great significance [10, 19, 29, 32].
There are three treatment methods in the selected articles, CD, CD+Marrow, and CD+A.B. The three treatment methods have different success rates. Further statistical analysis shows that composite bone marrow or autologous bone can significantly improve the success rate. The success rate of CD+Marrow (74.0%) and the success rate of CD+A.B (81.0%) are both higher than the overall success rate (65.0%), and CD+A.B has the highest success rate. In addition, in the study using CD+A.B, the success rate of only one study [5] is lower than the overall success rate.
The authors noted that in addition to the above methods, there were reports of core decompression with vascular pedicle bone graft, core decompression combined with bone debridement, and core decompression combined with tantalum rod implantation, all of which achieved satisfactory clinical results [46, 47].
Twenty-seven studies (2120 hips) detail the conversion to THA under different treatments. Both CD+A.B and CD+Marrow significantly reduce the rate of conversion to THA compared to CD. Twenty-six studies (1752 hips) detail the radiographic progression under different treatments. Both methods significantly reduce the rate of radiographic progression compared to CD. These two results are also consistent with the success rate of three treatment methods.
Three studies [27, 33, 36] added additional bone morphogenetic proteins (BMP) during treatment, which caught our interest in this substance. Exogenous BMP has a positive effect on the treatment of femoral head necrosis [48]. BMP is widely present in the bone matrix, which induces osteogenic cells in normal bone tissue and generates bone and cartilage tissue in bone and surrounding soft tissues [49]. Zhuo et al. [36] believe that the addition of BMP can promote the repair of the femoral head, cure, or delay the progression of the disease.
Two studies [26, 30] used graft materials of allogeneic bone composite autologous bone during the treatment, which is also the current development trend of bone transplantation. Autologous bone provides the best osteogenic and osteoinductive capacity without immune rejection [50]. However, its defects are also very obvious, such as prolonged operation time, increased trauma area of the patient, insufficient bone supply and many complications in the donor site [51]. The use of allogeneic bone can avoid the defects of autologous bone, and its osteogenic and osteoinductive ability is also widely recognized. With the deepening of scientific research, the problem of immune rejection and disease transmission in allogeneic transplantation is also a very good solution [52, 53]. The prospect of application of allogeneic bone in the treatment of femoral head necrosis is worth looking forward to.
Limitation
The current meta-analysis has certain limitations. First, there were only three RCTs in these studies, which led to a lower than expected level of evidence for our comprehensive comparison. Second, each study has different definitions of success, and assessing the diversity of standards will inevitably lead to bias in the final combined results. Third, some of the research lacks some important information, for example, etiology, complications, and postoperative rehabilitation of patients, this will lead to some factors that can only be used for simple calculation and analysis, and statistical tests cannot be performed. Finally, some innovative treatments are not included in the study, and the emergence of new methods requires a period of case accumulation in order to get a larger sample, which requires constant updating of the study in the future.
Conclusion
Core decompression is an effective and safe method of treating ONFH. The combined use of autologous bone or bone marrow can increase the success rate. For advanced femoral head necrosis, the use of CD should be cautious. High-quality randomized controlled trials and prospective studies will be necessary to clarify the effects of different etiology factors, treatments, and postoperative rehabilitation. Until then, the surgeon can choose core decompression to treat ONFH depending on the patient’s condition.
Acknowledgments
I would like to express my special thanks to my partners for the encouragement and support they gave me during my study. Thanks to my girlfriend, Miss Sun, for her support for my life and research.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.
Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.
Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.
Update Orthopädie und Unfallchirurgie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
